Serum S-100β Elevated in Septic Shock Patients with Delirium
By LabMedica International staff writers Posted on 30 Aug 2018 |
Image: An S-100β (Human)-ELISA Kit (Photo courtesy of Yanaihara Institute).
A high prevalence of delirium is observed in sepsis, yet specific markers for this brain dysfunction in sedated patients are still lacking. Cytoplasmic low molecular weight calcium-binding protein, S-100β, is a commonly used nonspecific marker for brain injury.
S-100β is glial-specific and is expressed primarily by astrocytes, but not all astrocytes express S-100β. It has been shown that S-100β is only expressed by a subtype of mature astrocytes that ensheath blood vessels and by NG2-expressing cells. Increases in S-100β levels have been evaluated whether there is an association in patients with delirium.
Scientists at the University of Oulu (Oulu, Finland) carried out an observational study included 22 patients with septic shock. Delirium was assessed by the Confusion Assessment Method (CAM) score for use in intensive care unit patients (CAM-ICU). Blood samples were obtained to measure inflammatory biomarkers: C-reactive protein (CRP), Procalcitonin (PCT), interleukin-6 (IL-6), IL-17, Tumor necrosis factor-alpha (TNF-α) and cerebral biomarkers such as S-100β, neuron-specific enolase (NSE), and two others. Patients were categorized according to the presence of delirium.
The scientists found that delirium was present in 10/22 of the patients (45.5%). Serum S-100β levels were above the laboratory cutoff value of 0.15 μg/L in 13/22 (59.1%) of the patients. The odds ratio for risk of developing delirium in cases with an S-100β greater than 0.15 μg/L was 18.0. Patients with delirium had higher plasma levels of IL-6 compared to those without; 138.3 pg/mL (range: 28.0-296.7) versus 53.6 pg/mL (range 109.3-505). There was a positive correlation between S100-β and IL-6 levels. Delirium patients had higher SOFA scores; 10 versus 7.
The authors concluded that delirium in septic shock was associated with an elevated protein S-100β when using a laboratory cutoff value of 0.15 μg/L and with more severe organ dysfunction during the ICU stay. The study was published on August 5, 2018, in the journal Acta Anaesthesiologica Scandinavica.
Related Links:
University of Oulu
S-100β is glial-specific and is expressed primarily by astrocytes, but not all astrocytes express S-100β. It has been shown that S-100β is only expressed by a subtype of mature astrocytes that ensheath blood vessels and by NG2-expressing cells. Increases in S-100β levels have been evaluated whether there is an association in patients with delirium.
Scientists at the University of Oulu (Oulu, Finland) carried out an observational study included 22 patients with septic shock. Delirium was assessed by the Confusion Assessment Method (CAM) score for use in intensive care unit patients (CAM-ICU). Blood samples were obtained to measure inflammatory biomarkers: C-reactive protein (CRP), Procalcitonin (PCT), interleukin-6 (IL-6), IL-17, Tumor necrosis factor-alpha (TNF-α) and cerebral biomarkers such as S-100β, neuron-specific enolase (NSE), and two others. Patients were categorized according to the presence of delirium.
The scientists found that delirium was present in 10/22 of the patients (45.5%). Serum S-100β levels were above the laboratory cutoff value of 0.15 μg/L in 13/22 (59.1%) of the patients. The odds ratio for risk of developing delirium in cases with an S-100β greater than 0.15 μg/L was 18.0. Patients with delirium had higher plasma levels of IL-6 compared to those without; 138.3 pg/mL (range: 28.0-296.7) versus 53.6 pg/mL (range 109.3-505). There was a positive correlation between S100-β and IL-6 levels. Delirium patients had higher SOFA scores; 10 versus 7.
The authors concluded that delirium in septic shock was associated with an elevated protein S-100β when using a laboratory cutoff value of 0.15 μg/L and with more severe organ dysfunction during the ICU stay. The study was published on August 5, 2018, in the journal Acta Anaesthesiologica Scandinavica.
Related Links:
University of Oulu
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms